According to Fortune Business Insights, the global follicle stimulating hormones market size was valued at USD 3.96 billion in 2025. The market is projected to grow from USD 4.21 billion in 2026 to USD 6.90 billion by 2034, exhibiting a CAGR of 6.37% during the forecast period from 2026 to 2034. North America dominated the market, accounting for a 31.81% market share in 2025.
The global follicle stimulating hormones market includes recombinant FSH, urinary-derived FSH, and FSH combination products. These therapies are used across controlled ovarian stimulation for IVF/ICSI, ovulation induction, male infertility or spermatogenesis induction, and fertility preservation.
The market is supported by the substantial global burden of infertility. According to the source, around 17.5% of adults worldwide, or approximately one in six people, experience infertility during their lifetime. This creates a significant long-term need for fertility treatments and related hormonal therapies.
Recombinant FSH products are increasingly adopted because of standardized dosing, self-administration options, and availability through pre-filled injection pens. Meanwhile, pharmaceutical companies are investing in personalized ovarian-stimulation protocols, biosimilars, and advanced formulations to expand treatment options.
For detailed market insights: https://www.fortunebusinessinsights.com/follicle-stimulating-hormones-market-111656
Increasing licensing, supply, development, and commercialization partnerships are a prominent trend in the follicle stimulating hormones market. Established pharmaceutical companies are collaborating with fertility-drug developers to utilize commercial infrastructure, reduce market-entry requirements, and accelerate product availability.
These partnerships are particularly relevant for recombinant and long-acting FSH products, which require specialized manufacturing, clinical validation, and regulatory approvals. For example, in September 2024, Organon collaborated with Shanghai Bao Pharmaceutical and Suzhou Centergene Pharmaceuticals for SJ02, an investigational long-acting FSH product, obtaining commercialization rights for mainland China.
The increasing number of IVF, ICSI, and other ART procedures is a major factor driving follicle stimulating hormones market growth. FSH-based medicines are administered during controlled ovarian stimulation to encourage the development of multiple ovarian follicles and facilitate the collection of sufficient eggs for fertilization.
As fertility clinics expand their capacity and patients undergo repeated treatment cycles, demand for recombinant FSH, urinary-derived FSH, and combination products is expected to increase. The source notes that in the U.K., 64,000 patients underwent more than 100,000 treatments and freezing cycles at HFEA-licensed clinics in 2024, highlighting sustained ART utilization.
Other factors supporting growth include rising infertility prevalence, delayed parenthood, expansion of fertility clinics and ART infrastructure, growing adoption of recombinant FSH, patient-friendly delivery systems, and geographic expansion of biosimilar and lower-cost FSH products.
Based on type, the market is segmented into recombinant FSH, urinary-derived FSH, FSH combination products, and others. The recombinant FSH segment is expected to lead the market. Its adoption is supported by standardized dosing and convenient administration options.
The market is divided into follitropin alfa, follitropin beta, urofollitropin, menotropins/hMG, corifollitropin alfa, and others. Menotropins/hMG held the largest market share in 2025, supported by its established use in controlled ovarian stimulation and combined FSH and luteinizing hormone activity.